Diabetic Gastroparesis Treatment Market

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. DIABETIC GASTROPARESIS TREATMENT MARKET ANALYSIS Diabetic Gastroparesis Treatment Market, By Product Type (Drugs (Gastroprokinetic Agents, Antiemetic Agents, Botulinum Toxin), Surgical Treatment Products (Gastric Electrical Stimulation (GES) Device, Percutaneous Endoscopic Gastrostomy (PEG) Kit, Parenteral Nutrition)), By Disease Indication (Compensated Gastroparesis, Gastric Failure), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

3. The global diabetic gastroparesis treatment market is estimated to account for US$ 3,069.8 Mn in terms of value in 2018 and is expected to reach US$ 4,252.2 Mn by the end of 2027. • Global Diabetic Gastroparesis Treatment Market: Drivers • Increasing prevalence of diabetes is expected to propel growth of the global diabetic gastroparesis treatment market over the forecast period. For instance, according to the study, ‘Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)’, published by the American Diabetes Association, 500 million people worldwide suffered from type 2 diabetes in 2018.

4. North America region held dominant position in the global diabetic gastroparesis treatment market in 2018, accounting for 38.5% share in terms of value, followed by Europe.

5. Global Diabetic Gastroparesis Treatment Market: Restraints • Lack of clinical evidence on improvement offered by prescription drugs is expected to hinder growth of the global diabetic gastroparesis treatment market. There is very little documented clinical evidence provided for prescription drugs for the treatment of diabetic gastroparesis. Metoclopramide, domperidon, and erythromycin are used for the treatment of diabetic gastroparesis. However, approvals of these drugs are inconsistent across countries, leading to lack of availability of consistent patient improvement data due to administration of these drugs. In emerging economies, the disease remains largely untreated or often treated through non-prescription OTC drugs, which again is responsible for dearth of clinical evidence regarding improvement in quality of life for patients after consuming these drugs for the treatment of diabetic gastroparesis.

6. Global Diabetic Gastroparesis Treatment Market: Opportunities  • Measures to support product approval and labeling claims for diabetic gastroparesis treatments is expected to offer lucrative growth opportunities for players in the global diabetic gastroparesis treatment market. For instance, in February 2019, a team of researchers affiliated with Boston Therapeutics, Inc. reported that The Diabetic Gastroparesis Symptom Severity Diary can be a reliable and valid measure that can be used to derive endpoints to evaluate treatment benefit in future diabetic gastroparesis interventional trials.

7. Drugs segment in the global diabetic gastroparesis treatment market was valued at US$ 1,924.5 Mn in 2018 and is expected to reach US$ 2,646.8 Mn by 2027 at a CAGR of 3.6% during the forecast period. • Market Trends/Key Takeaways • The market is witnessing R&D in non-invasive approaches for the treatment of diabetic gastroparesis. For instance, a pilot study presented at the 2019 annual meeting of the North American Neuromodulation Society assessed the effectiveness of the gammaCore hand-held vagal nerve stimulator for the treatment of gastroparesis. • Gastric Per-Oral Endoscopic Pyloromyotomy (GPOEM) is a safe and effective therapy for refractory gastroparesis. For instance, researchers from Emory University (U.S) assessed the safety and efficacy of GPOEM and compared clinical outcomes between diabetic and non-diabetic cohorts and found that patients with predominant nausea/vomiting and short duration of diabetic gastroparesis may opt for GPOEM.

8. Regulations • U.S. • ICD-10-CM • Reimbursement claims with a date of service on or after Oct 1, 2015 require the use of ICD-10-CM codes • This is the American ICD-10-CM version of K31.84. Other international ICD-10 versions may differ • 61 (diabetes with neurological manifestations) • 3 (gastroparesis) • 43 (Type 1 diabetes mellitus with diabetic autonomic [poly]neuropathy)

9. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • Buy Now Reference:: https://www.coherentmarketinsights.com/market-insight/diabetic-gastroparesis-treatment-market-3603

10. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

11. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

12. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/